Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1976 2
1977 1
1981 1
1989 1
1991 2
1992 4
1993 4
1994 4
1995 1
1996 4
1997 1
1998 3
1999 4
2000 4
2001 10
2002 13
2003 8
2004 12
2005 14
2006 15
2007 29
2008 25
2009 28
2010 45
2011 50
2012 49
2013 70
2014 73
2015 71
2016 72
2017 70
2018 74
2019 109
2020 136
2021 149
2022 139
2023 132
2024 111
2025 107

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,454 results

Results by year

Filters applied: . Clear all
Page 1
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV; RedirecTT-1 Investigators and Study Group. Cohen YC, et al. Among authors: min ck. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536. N Engl J Med. 2025. PMID: 39778168 Clinical Trial.
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carb… See abstract for full author list ➔ Skoulidis F, et al. Among authors: min c. Nature. 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9. Nature. 2024. PMID: 39385035 Free PMC article.
Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.
Lai K, Sun D, Dai R, Samoro R, Park HS, Åstrand A, Cohen D, Jison M, Shih VH, Werkström V, Yao Y, Zhang Y, Zheng W, Zhong N; MIRACLE Study Investigators; Principle investigators; Albert A Jr, Jianping B, Bi C, Lijun C, Mei C, Min C, Ping C, Zhimin C, Chih-Feng C, Sook CY, Xiuhua F, Xiwen G, Wei G, Wei H, Zhihai H, Wei HX, Kewu H, Mao H, Grace Dawn IM, Inbeom J, Luning J, Mingyan J, Shanping J, Meiling J, Jian K, Woo KJ, Sang-Ha K, Jiulong K, Ping-Hung K, Jie L, Manxiang L, Minjing L, Ruoran L, Wen L, Xianhua L, Yanming L, Yong LS, Chuanhe L, Chuntao L, Jing L, Xiaoxia L, Huiyu L, Zhuang L, Shengxi M, Liangping M, Hoon MK, Lin M, Choon-Sik P, Sim PH, Hye-Kyung P, Jung-Won P, Diahn-Warng P, Ronnie S, Guochao S, Debin S, Dejun S, Chun-Hua W, Guangfa W, Limin W, Xuefen W, Yan W, Liping W, Haihong W, Yi X, Zuke X, Canmao X, Jin-Fu X, Xingxiang X, Xiyuan X, Jianping Y, Hongzhong Y, Joo YH, Wencheng Y, Jin Z, Longju Z, Min Z, Wei Z, Jianping Z, Ziwen Z, Xiaoli Z, Yingqun Z; Other investigators; AstraZenenca; ClinChoice. Lai K, et al. Among authors: min c. Respir Med. 2024 Apr 1:107611. doi: 10.1016/j.rmed.2024.107611. Online ahead of print. Respir Med. 2024. PMID: 38570145 Free article.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Among authors: min ck. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Enhanced efficacy of glycoengineered rice cell-produced trastuzumab.
Shin JH, Oh S, Jang MH, Lee SY, Min C, Eu YJ, Begum H, Kim JC, Lee GR, Oh HB, Paul MJ, Ma JK, Gwak HS, Youn H, Kim SR. Shin JH, et al. Among authors: min c. Plant Biotechnol J. 2024 Nov;22(11):3068-3081. doi: 10.1111/pbi.14429. Epub 2024 Jul 17. Plant Biotechnol J. 2024. PMID: 39016470 Free PMC article.
1,454 results